Vasodilators after myocardial infarction-ISIS IV

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Previous small trials suggested high benefits from vasodilators in acute myocardial infarction (MI), but with significant statistical uncertainty.
• The role of early angiotensin-converting enzyme (ACE) inhibitors in acute MI was unclear, with potential risks like hypotension.
• Nitrates were found to be safe but offered no statistically significant mortality reduction when used routinely.

Purpose of the Study:

• To clarify the benefits and risks of early pharmacological interventions in acute myocardial infarction (MI).
• To evaluate the efficacy of nitrates, magnesium, and ACE inhibitors in the early phase of acute MI.

Main Methods:

• Analysis of data from large-scale clinical trials, including GISSI-3 and International Studies of Infarct Survival (ISIS-4).
• Comparison of mortality rates and adverse events associated with different drug classes.

Main Results:

• Routine nitrate use in acute MI showed no statistically significant mortality reduction.
• Magnesium administration in ISIS-4 yielded disappointing results with a slight excess mortality.
• Routine early administration of ACE inhibitors demonstrated a statistically significant 5-10% reduction in mortality, particularly in patients with left ventricular damage.

Conclusions:

• ACE inhibitors are beneficial in the early phase of acute MI, offering significant mortality reduction.
• While nitrates are safe, their routine early use does not provide significant mortality benefits.
• A strategy of initial ACE inhibitor treatment for all acute MI patients, followed by reassessment, is recommended for maximal benefit.